AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 292 min read$BSX

What Is Behind The Move In Boston Scientific Stock?

Boston Scientific (BSX) stock fell 5.8% after Q3 2026 results and lowered outlook due to a cyberattack. The attack reduced sales by $150M. Revenue was $5.14B, beating estimates, but growth slowed. Full-year revenue growth forecast cut to 4%. Peers mostly rose. BSX stock down 58.6% over a year.

Original reporting
finance.yahoo.com
Published Oct 29, 2026, 1:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 1:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
What Is Behind The Move In Boston Scientific Stock? — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$BSXBearishHigh
01

Why it matters

The earnings miss and guidance cut drove a 5.8% share decline, while peers showed modest gains, indicating a company‑specific issue.

02

Market read

The new guidance and cyberattack impact create immediate trading opportunities for BSX, with likely continued downside pressure.

03

What to watch

Potential upside from upcoming Penumbra acquisition and any insurance recoveries from the cyber incident.

Relevance 8/10Novelty 8/10Timing: intraday today

Background

Boston Scientific disclosed a cyberattack that halted manufacturing for eight days, cutting Q3 sales by $150 M and prompting a guidance downgrade.

Company-level read

Ticker impact

$BSXBearishHigh confidence
Context

Boston Scientific reported Q3 results, cut full-year organic revenue guidance to 4% and its stock fell 5.8% on the same day.

Expected impact

likely downward pressure as the market prices in the reduced revenue outlook and cyber‑attack disruption.

Evidence & confidence

The earnings release includes a material guidance reduction and a disclosed $150 M sales hit, which are new and significant.

Market effects

Sector

Health‑care sector may see relative outperformance as peers like Medtronic and Stryker posted gains.

Regional

U.S. market impact limited to health‑care stocks; broader indices unchanged.

Global

Minimal global effect beyond U.S. health‑care investors.

Counterpoint

What could challenge this read

If the cyberattack impact is short‑lived, the stock could rebound on the back of solid revenue beat.

Key entities

  • company
    Boston Scientific

    Medical device maker reporting Q3 2026 results.

Read at source← All news

StoryBoston Scientific cuts FY‑2026 outlook as August cyberattack drags sales and earnings

Also covered by

5 outlets

Related articles

OCT 29
$BSXMedAI 8/10

Boston Scientific Corp (BSX) (Q3 2026) Earnings Call Highlights: Cyber Incident Slashes

Boston Scientific (BSX) reported Q3 2026 earnings below expectations due to a cyber incident, with organic sales growth of 1.5% and adjusted EPS of $0.73. The company expects continued pressure in 2027 but anticipates growth from new product launches and market expansions. BSX plans $500M in savings from restructuring and expects to close the Penumbra acquisition in early 2027.

finance.yahoo.com7 min
OCT 29
$BSXMedAI 8/10

Boston Scientific Corporation net sales up 1.5 % to USD 5.138B in Q3 2026

Boston Scientific (BSX) reported Q3 2026 net sales of $5.138B, up 1.5%. GAAP EPS was $0.40, down from $0.51 a year ago, while adjusted EPS was $0.73, slightly lower than the previous year. The company faced challenges, including a cybersecurity incident, but remains confident in its long-term strategy. Full-year net sales growth is now expected to be around 4.25% on a reported basis and 3.75% organically, with adjusted EPS projected between $3.16 and $3.18.

medicalbuyer.co.in5 min
OCT 29
$BSXMed

Oppenheimer downgrades Boston Scientific stock rating on growth concerns

Oppenheimer downgraded Boston Scientific (BSX) to Perform from Outperform due to growth concerns, citing weak Q3 results and a lack of expected growth in 2027. The stock is down 55.5% YTD to $42.43. BSX reported Q3 revenue of $5.14B, meeting expectations but missing EPS forecasts. Analysts lowered price targets and earnings estimates, citing a cyberattack's impact and declining product franchises. BSX's organic growth was 1.5% YOY, below guidance.

investing.com2 min
OCT 29
$MUMed

Wall Street ends higher as Fed holds key rate steady

U.S. stock indexes rose after the Fed kept rates unchanged, upgrading its economic outlook but noting elevated inflation. Investors expect a December rate hike. Micron and SK Hynix shares surged on strong earnings. Microsoft gained, while Alphabet dropped in extended trading. The Dow, S&P 500, and Nasdaq all closed higher.

newstribune.com7 min
OCT 29
$BSXHighAI 8/10

Key facts: BSX Q3; EPS cut; China, EP/Watchman weak; Penumbra Q1'27

Boston Scientific (BSX) reported Q3 sales of $5.138B, up 1.5% YoY, with adjusted EPS of $0.73. The company cut FY2026 adjusted EPS guidance to $3.16–3.18, citing China pricing pressure and weakness in EP/Watchman devices. BSX expects Q4 sales to decline 1%–3%. The $14.5B Penumbra acquisition is delayed to Q1 2027 due to regulatory and financing issues. Needham maintained a Buy rating with a $48 target.

tradingview.com1 min